Drug costs in context: assessing drug costs in cost-of-illness analyses.
Date
2022-07-21Journal
Drugs in ContextPublisher
Bioexcel Publishing Ltd.Type
Article
Metadata
Show full item recordAbstract
Cost-of-illness (COI) studies attempt to measure and describe the costs associated or attributed to a specific disease, but there are several considerations for measuring and interpreting drug costs estimates. The complexity of the pharmaceutical supply chain and contractual relationships between manufacturers, wholesalers, pharmacies and payers create challenges for researchers attempting to include drug costs in COI analyses. This article aims to provide contextual information for a general audience interested in conducting or evaluating COI studies that may include drug costs and to describe key factors to consider when reviewing drug costs in the peer-reviewed literature.Rights/Terms
Copyright © 2022 Mattingly II TJ, Weathers S.Identifier to cite or link to this item
http://hdl.handle.net/10713/19574ae974a485f413a2113503eed53cd6c53
10.7573/dic.2022-5-4
Scopus Count
Collections
Related articles
- Cost-of-illness studies : a review of current methods.
- Authors: Akobundu E, Ju J, Blatt L, Mullins CD
- Issue date: 2006
- The Economic Costs of Type 2 Diabetes: A Global Systematic Review.
- Authors: Seuring T, Archangelidi O, Suhrcke M
- Issue date: 2015 Aug
- Cost-of-illness studies. Useful for health policy?
- Authors: Koopmanschap MA
- Issue date: 1998 Aug
- Quantifying The Economic Burden Of Drug Utilization Management On Payers, Manufacturers, Physicians, And Patients.
- Authors: Howell S, Yin PT, Robinson JC
- Issue date: 2021 Aug
- Methodological Considerations for Cost of Illness Studies of Enteric Fever.
- Authors: Mejia N, Ramani E, Pallas SW, Song D, Abimbola T, Mogasale V
- Issue date: 2020 Jul 29